Mark Ratner

Nov 6, 2024 | insights.citeline.com | Mark Ratner

Nestlé Gets Serious With Seres Deal08 Mar 2016 • By Mark RatnerThe January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.

Apr 18, 2024 | invivo.citeline.com | David Wild |Lucie Ellis-Taitt |Melanie Senior |Mark Ratner

Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support.

Jan 24, 2024 | invivo.citeline.com | Mark Ratner

Analysis Executive Summary Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape. You may also be interested in...  Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!

Oct 17, 2023 | medtech.citeline.com | Marion Webb |Mark Ratner |Hannah Daniel |Brian Bossetta

Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support.

Oct 17, 2023 | medtech.pharmaintelligence.informa.com | Mark Ratner

Analysis Executive Summary Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics. You may also be interested in...  Existing Subscriber? Sign in to continue reading. New to Medtech Insight? Start a free trial today!